News
Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...
The findings add to other research showing a lower risk of obesity-related cancers in patients taking GLP-1 drugs, a class of ...
After questions and criticism online, Janelle Rohner says she should have disclosed her decision to take a GLP-1.
Newly recognized issues, including extreme fatigue with excessive weight reduction, bone loss, and abdominal pain, point to ...
New review confirms psychiatric safety of commonly used glucagon-like peptide 1 receptor agonists among patients without ...
1d
MedPage Today on MSNGLP-1 Agonists May Help Prevent Weight Gain for People Trying to Quit SmokingXavier said that patients are often reluctant to quit smoking because they are fearful that they will gain weight. By adding ...
Explore more
If you're one of the millions of Americans who have used or thought about using GLP-1 weight-loss drugs, it’s important to ...
The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off ...
David Kessler has lost more than 60 pounds on weight-loss drugs and believes they can change the trajectory of chronic ...
GLP-1 receptor agonists may reduce risk for obesity-related cancers among people with diabetes compared with dipeptidyl ...
Dr. Rubinstein has years of experience working with patients to help them achieve their desired goals in a realistic, ...
VinFuture Prize holds the distinction of being the first major international science and technology award to recognize and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results